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Abstract: Osteoporosis is a progressive and debilitating disease characterized by a massive 
bone loss with a deterioration of bone tissues, and a propensity for a fragility fracture. 
Strontium ranelate is the first antiosteoporotic treatment that has dual mode of action and 
simultaneously increases bone formation, while decreasing bone resorption, thus rebalancing 
bone turnover formation. Strontium ranelate rebalances bone turnover in favor of improved 
bone geometry, cortical thickness, trabecular bone morphology and intrinsic bone tissue 
quality, which translates into enhanced bone strength. This review describes the mechanism 
of the strontium ranelate action and its effects on bone mineral density, bone turnover, and 
osteoporotic fractures. The efficacy of strontium ranelate in postmenopausal osteoporosis 
treatment to reduce the risk of vertebral and hip fractures has been highlighted in several 
randomized, controlled trials. Treatment efficacy with strontium ranelate has been documented 
across a wide range of patient profiles: age, number of prevalent vertebral fractures, body 
mass index, and a family history of osteoporosis. Because strontium ranelate has a large 
spectrum of efficacy, it can be used to treat different subgroups of patients with postmeno-
pausal osteoporosis. Strontium ranelate was shown to be relatively well tolerated and the 
safety aspects were good. Strontium ranelate should be considered as a first-line treatment 
for postmenopausal osteoporotic patients.
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Introduction
Osteoporosis is a systemic skeletal disease characterized by a decreasing bone mass 
and a micro architectural deterioration of bone tissue, leading to a consequent increase 
in bone fragility and a susceptibility to fractures.1 After menopause, bone turnover 
acceleration induces an imbalance between bone resorption and formation, leading to 
a final postmenopausal bone loss. Because osteoporosis is considered to be the main 
cause of fractures in postmenopausal women, it represents an important and potentially 
preventable health problem.2
Currently available pharmacological treatments for osteoporosis modify bone micro 
architecture acting on one component of the bone remodelling process. Bisphospho-
nates reduce bone resumption, while teriparatide and other forms of parathormone act 
primary in the stimulation of bone formation.3
Recently, a new agent, strontium ranelate (SR), has been licensed in Europe for 
osteoporosis treatment. SR is the first osteoporotic treatment with a dual mode of 
action; it simultaneously increases bone formation and decrease bone resumption, 
switching the turnover equilibrium to bone formation.International Journal of Women’s Health 2010:2 
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Hypothetical mechanisms of action, the effects on 
bone mineral density (BMD), bone turnover markers, 
antifracturative efficacy and safety of SR are discussed in 
this work.
Mechanism of action
Strontium is a bone-seeking element closely related to 
calcium. SR is composed of two atoms of stable strontium 
and one molecule of ranelic acid.4 SR is a treatment for 
osteoporosis and unlike other drugs, has a dual effect on 
bone remodeling, being able to stimulate bone formation by 
osteoblasts, a property shared with bone-forming agents, and 
to inhibit bone resumption by osteoclasts, as antiresumptive 
agents.5,6
Despite our current knowledge on the cellular effects of 
SR on osteoblasts, the exact molecular mechanisms involved 
remain elusive. In particular the mechanism by which SR 
reduces fracture risk is not completely understood. It has been 
hypothesized that strontium could activate signaling path-
ways through a cation-sensing receptor which is expressed 
in bone cells because of its atomic and ionic properties as a 
divalent cation that closely resembles the calcium ion. SR 
could act as a calcium-like entity for the well known anabolic 
effects of calcium itself in bone. However preliminary data 
demonstrated that SR activates sensing receptors that are 
expressed at all stages of osteoblast activity.7,8 and there is 
well established evidence that strontium affects the activity 
of bone cells in vitro.
In vitro, SR enhances the replication of preosteoblastic 
cells and, secondarily, bone matrix synthesis.9 It activates 
gene expression in osteoblasts, and the formation of min-
eralized colony-forming unit-osteoblasts (CFU-obs). Bone 
marrow-derived stromal cells in culture, when exposed 
to SR, displayed a significant increase in the expression 
of the master gene, Runx2, as well as bone sialoprotein 
(BSP), and this was associated with a significant increase 
in the formation of CFU-obs. In particular, genes activated 
by SR depend on the differentiation stage: Runx2 and 
BSP in bone marrow-derived cells, Runx2, osteocalcin 
in preosteoblasts, BSP, and osteocalcin in mature osteo-
blasts (Figure 1). At the same time, the strontium dose 
dependently decreases pre-osteoclast differentiation and 
bone resorption.10,11 In mouse calvaria cultures, strontium 
inhibits dose-dependent bone resorption.12 In another study 
the resorbing activity of strontium was not mediated by 
prostaglandin E2, but osteoclast cells were required for its 
effect. Destruction of osteoclasts decreases strontium13 
antirespective effects.
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Figure  Genes activated by strontium ranelate depend on the differentiation stage.
Abbreviation: BSP, bone sialoprotein.International Journal of Women’s Health 2010:2 
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In vivo studies performed in various rodent models such as 
immobilization-induced osteopenia and ovariectomy-induced 
osteoporosis in intact animals, indicate that strontium causes 
an imbalance of bone turnover in favor of bone forma-
tion.14,15
SR increases bone strength and this effect is related to 
positive influences on most of the determinants of bone 
strength such as bone mass, geometry, microarchitecture, 
and bone tissue quality. Bone static histomorphometry and 
microcomputed tomography demonstrated a dose-dependent 
increase in trabecular bone volume, trabecular number and 
thickness, connectivity, and cortical thickness, as assessed 
at the level of the tibia. SR improved bone geometry by 
increasing the external diameter and cortical thickness of 
the long bones through periosteal and endosteal apposition, 
respectively. Bone mechanical properties is characterized 
by an increase not only in the maximal load but also by 
a dramatic improvement in energy to failure, which was 
essentially due to plastic energy increase.16–19
Clinical studies
Secondary endpoints: bone mineral 
density and bone turnover markers
Bone mineral density
In the STRATOS study, 353 osteoporotic postmenopausal 
women with at least one previous vertebral fracture and a 
lumbar T-score of less than 2.4 were randomized to receive 
a placebo, SR 500 mg per day, 1 g per day, or 2 g per day. 
Lumbar BMD measured by dual-energy X-ray absorpti-
ometry (DXA) was the primary parameter investigated for 
efficacy.
In the STRATOS study, the annual increase in lumbar 
BMD in the 2 g per day group (+7.3% per year) was signifi-
cantly higher than in the placebo group (P  0.001). The 
minimum dose at which SR was effective in preventing bone 
loss in early postmenopausal nonosteoporotic women and in 
the treatment of postmenopausal osteoporosis was 1 g per 
day and 2 g per day, respectively.20
The SOTI trial included 1649 postmenopausal women 
aged 70 years on average with osteoporosis defined by a 
lumbar BMD of 0.731 ± 0.125 g/cm2 and/or at least one 
prevalent vertebral fracture (this last criterion was present 
in 87.5% of included patients). Over a period of three years, 
in the SR group a baseline of 12.7% increase in BMD was 
observed in the lumbar spine, 7.2% in the femoral neck, and 
8.6% in the total hip (P  0.001 for all three comparisons 
with baseline values).21
The  TROPOS  trial  included  5091  osteoporotic 
postmenopausal women aged 74 years (or 70 years with 
one risk factor for an osteoporotic fracture), with a femoral 
neck BMD of  0.600 g/cm2. In TROPOS, at three years in 
the SR group a 5.7% baseline percentage increment in BMD 
was observed at the femoral neck and 7.1% at the total hip 
(P = 0.001), compared with the placebo group.22
In these clinical trials, there were impressive BMD 
enhancements in the spine with the spine curve similar to 
that for parathyroid hormone (PTH). However, some cau-
tion is necessary for a correct interpretation of these results 
because some of this effect could be due to the higher atomic 
number of strontium (z = 38) compared with calcium (z = 20) 
affect when BMD is measured by DXA. X-ray attenuation 
for strontium atoms in the bone is stronger than calcium 
atom attenuation. However, when the DXA scanner software 
calculates BMD from measured X-ray transmission factors, 
the increased attenuation caused by bone strontium content 
(BSC) is considered as calcium content attenuation and this 
can lead to an artificial increase in BMD. Although a com-
mendable effort was made in the SOTI trial to correct the 
BMD data for the atomic number effect of strontium, there 
is clearly a considerable uncertainty about the accuracy of 
the corrections that have been done.21,23 Furthermore a strong 
relationship between the increase in BMD and a subsequent 
reduction of a new vertebral or hip fracture risk has been 
demonstrated in SR-treated patients, indicating that BMD 
level monitoring may be valuable in these patients. After 
treatment withdrawal, patients who switched to a placebo 
after four years experienced a significant reduction in BMD, 
showing how SR effects had been progressively reversible and 
reflecting the clearance of strontium from the bone.24
Bone turnover markers
In the SOTI and TROPOS studies administration of SR 
resulted in increased levels of serum bone alkaline phos-
phatase compared with the placebo group from the third 
month (8.1%; P = 0.001); this difference persisted over the 
first three and four years of the SOTI study, while the serum 
telopeptide of type I collagen decreased from the third month 
(12.2%; P  0.001). The pattern of change in these markers 
of bone remodeling is different from the pattern documented 
as occurring with antiresorptive therapies, such as bisphos-
phonates and selective estrogen receptor modulators (which 
decrease markers of bone resorption and bone formation), or 
with anabolic therapy such as PTH (which increases mark-
ers of bone resorption and bone formation).25 In patients 
treated with SR, there was a remodeling marker divergence International Journal of Women’s Health 2010:2 
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(increase in bone formation, decrease in bone resorption), 
which underscores the difference in the mechanism of action 
of SR compared with traditional antiresorptive agents and 
paratormon. Changes were moderate, but opposite and con-
comitant, according with the potential mechanism of action 
of the drug.
Primary endpoints:  vertebral 
and nonvertebral fractures
In the STRATOS study, there was a significant reduction 
of patients experiencing new vertebral deformities in the 
second year of treatment with 2 g/d SR (relative risk [RR], 
0.56; 95% confidence interval [CI]: 0.35 to 0.89).
In the SOTI study at the end of the first year of 
treatment, there was a 49% lower risk reduction of a new 
vertebral fracture in the SR group than in the placebo group 
(incidence of 6.4% versus 12.2%; RR, 0.51; 95% CI: 0.36 
to 0.74; P  0.001), and a 52% lower risk of symptomatic 
fracture (3.1% versus. 6.4%; RR, 0.48; 95% CI: 0.29 to 0.80; 
P = 0.003). Over the entire three-year study period, the SR 
group showed a 41% risk reduction for a new vertebral frac-
ture than did the placebo group (20.9% versus 32.8%; RR, 
0.59; 95% CI: 0.48 to 0.73; P  0.001). On the basis of this 
data, nine patients would need to be treated for three years 
with SR in order to prevent a vertebral fracture in one patient 
(95% CI: 6 to 14). A 33% decrease in vertebral fracture risk 
was observed over a four-year period (RR, 0.67; 95% CI: 
0.53 to 0.81; P  0.001).
Effective action of SR on nonvertebral fractures has been 
evaluated in the TROPOS trial, which included 5091 osteo-
porotic postmenopausal women aged 74 years (or 70 years 
with one risk factor of osteoporotic fracture), with a femoral 
neck BMD of  0.600 g/cm2.
The primary parameter of efficacy taken into consider-
ation was the incidence of patients with at least one osteopo-
rotic peripheral fracture. In the intention-to-treat population, 
SR was associated with a 16% RR reduction of nonvertebral 
fractures over a three-year follow-up period (RR, 0.84; 95% 
CI: 0.70 to 0.99; P = 0.04). SR treatment was associated with 
a 19% risk reduction in major nonvertebral osteoporotic 
fractures (RR, 0.81; 95% CI: 0.66; 0.98; P = 0.031).
A 36% risk reduction of hip fracture (RR, 0.64; 95% 
CI: 0.412 to 0.997; P = 0.046) for the high-risk fracture 
subgroup (women 74 years and with femoral–neck BMD 
T–score –3) was also associated with the treatment.
Over a five-year period data came from 4935 patients for 
intention-to-treat analysis. There was a 15% decrease in risk 
for nonvertebral fractures over five years (RR, 0.85; 95% 
CI: 0.73 to 0.99; P = 0.032). There was a 43% decreased 
risk of hip fracture in a subset of 1128 patients with a clear 
indication of high risk for fractures, ie, aged 74 years or more, 
and a BMD t-score 2.4 at both the lumbar spine and the 
femoral neck; in this subset, the risk reduction was 0.57 (95% 
CI: 0.33 to 0.97; P = 0.036).26 Although these results were 
obtained in a post hoc analysis, it should be pointed out that 
no other trial has been conducted thus far; with medication 
versus placebo during a five-year period, with nonvertebral 
fracture incidence as an end-point (Table 1).
Data from SOTI and TROPOS trials were pooled to 
evaluate the efficacy of SR on antivertebral fractures in 
women with lumbar spine (LS) osteopenia. In this case, 
treatment reduced the risk of vertebral fracture by 41% (RR, 
0.59; 95% CI: 0.43 to 0.82), by 59% (RR, 0.41; 95% CI: 0.17 
to 0.99) in the patients with no prevalent fractures, and by 
38% (RR, 0.62; 95% CI: 0.44 to 0.88) in the patients with 
prevalent fractures. In women with osteopenia at vertebral 
and femoral bone, treatment reduced the risk of fracture by 
52% (RR, 0.48; 95% CI: 0.24 to 0.96).27
Other data from SOTI and TROPOS trials were pooled 
to evaluate the antifracture effective action of SR in elderly 
patients. In these patients (80 years) the risk of vertebral, 
nonvertebral, and clinical symptomatic (vertebral and 
nonvertebral) fractures were reduced within one year by 59% 
(P = 0.002), 41% (P = 0.027), and 37% (P = 0.012), respec-
tively. At the end of three years, vertebral, nonvertebral, 
and clinical fracture risks were reduced by 32% (P = 0.013), 
31% (P = 0.011), and 22% (P = 0.040), respectively.28 The 
medication was well tolerated, and the safety profile was 
similar to that in younger patients.
Over the five years of treatment there was a relatively 
high drop-out (47%) but this was similar to the drop-out 
Table  Antifracture efficacy of strontium ranelate
Fracture Duration 
(years)
Risk reduction (95% 
confidence interval)
vertebral 1 0.51 (0.36, 0.74)
vertebral 3 0.59 (0.48, 0.73)
vertebral 4 0.67 (0.53, 0.81)
Clinical vertebral 1 0.48 (0.29, 0.80)
Clinical vertebral 3 0.62 (0.47, 0.83)
Nonvertebral 3 0.84 (0.70, 0.99)
Nonvertebral 5 0.85 (0.73, 0.99)
Hip (post hoc)* 3 0.64 (0.41, 0.99)
Hip (post hoc)** 5 0.57 (0.33, 0.97)
Notes: *Age 74 years; t-score hip -2.4; **Age 74 years; t-score hip and 
spine -2.4.International Journal of Women’s Health 2010:2 5
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rate over three years of the clinical trial with risedronate 
(42%).29 A comparison with other studies cannot be done 
because presently there is a lack of double blind long-term 
studies like this one.
Safety
SR is relatively well tolerated. Side effects include nausea, 
diarrhea, and headache, which usually resolve over time. In 
SOTI the most common adverse events were nausea and diar-
rhea (6.1% versus 3.6% in the placebo group). The difference 
between the two groups disappeared after the first three months. 
A slight increase in the annual incidence of venous thrombo-
embolism (0.9% versus 0.6%) was observed at 3 years, but 
remained unchanged following the third year, without any 
underlying potential mechanism, as there is no known interac-
tion between SR and parameters of hemostasis.
During post–marketing surveillance, isolated cases of 
hypersensitivity syndrome or drug rash with eosinophilia 
and systemic symptoms have been reported. This syndrome 
is associated with the appearance of skin reactions, fever 
and systemic findings, hypereosinophilia, hepatic abnormali-
ties, and renal impairment. The syndrome is very rare, with 
severe hypersensitivity reaction occurring within 1–8 weeks 
from the beginning of the treatment and resulted 16/570,000 
patients years exposure and two death. This can be com-
pared with Stevens–Johnson syndrome as observed with 
raloxifene or bisphosphonates.30 The drug intake should be 
stopped if there is rash occurrence at the beginning of the 
treatment. This mechanism for this syndrome can not be 
explained.31,32
Although these are rare side effects, SR, compared with 
a placebo, is the only antiosteoporotic agent for which an 
improvement in quality of life has been detected using a 
sensitive osteoporosis specific questionnaire in a large pro-
spective placebo controlled study with a 3-year follow-up 
period. Others antiosteoporotic agents such as alendronate 
and risedronate have been shown to improve quality of life 
although statistical relevance of the studies done is limited by 
the number of patients and by a short follow-up time.33
Conclusion
SR reduces vertebral, nonvertebral, and major nonvertebral 
fractures over 1, 3, 4, and 5 years. Its spectrum of activity 
covers women with osteopenia, osteoporosis, and severe 
osteoporosis. It is effective in reducing both vertebral and 
nonvertebral fractures, including hip fractures.
BMD may be used as a monitoring tool for SR, because 
early changes are predictive of long-term fracture reduction. 
Biochemical markers of bone turnover reflect the uncoupling 
between resorption and formation. The safety profile in 
strontium ranelate is more positive if compared with other 
antiosteoporosis medications currently available on the 
market. SR should be considered as a first-line treatment for 
postmenopausal osteoporotic women because of its safety 
and effective action.
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